Affiliation: Bristol-Myers Squibb
- The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trialRobert Frederich
Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ, 08543, USA
Diabetol Metab Syndr 4:36. 2012..abstract:..
- Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataMichael E Cobble
Canyons Medical Center, Sandy, UT, USA
Cardiovasc Diabetol 11:6. 2012....
- A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesRobert Frederich
Bristol Myers Squibb, Princeton, NJ 08543, USA
Postgrad Med 122:16-27. 2010..The objective was to assess the relative risk (RR) for cardiovascular (CV) events across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 diabetes mellitus...
- Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitusChetan S Karyekar
Bristol Myers Squibb, Princeton, NJ, USA
Clin Interv Aging 8:419-30. 2013..To assess safety and efficacy of saxagliptin in older patients with type 2 diabetes mellitus (T2DM)...